Aissel launches agentic AI assistant for life sciences KOL intelligence

Aissel Technologies on July 23 launched konectar AI, or kAI, a conversational AI layer inside its konectar platform for life sciences teams in North America, Europe and Asia-Pacific. The company says the tool cuts research time, improves KOL targeting and adds traceable, GDPR-compliant intelligence for Medical Affairs, commercial and strategy teams.

Why it matters: - Life sciences teams often spend weeks pulling together KOL profiles, influence maps and competitive intelligence. - kAI is designed to turn that workflow into minutes, which could speed engagement planning, congress prep and launch decisions. - The launch matters for teams that need fast answers without sacrificing traceability or compliance.

What happened: - Aissel Technologies launched konectar AI, or kAI, on July 23, 2026. - kAI is an agentic AI assistant embedded natively in konectar, Aissel Technologies' KOL management platform. - The product is available to existing clients and new enterprise customers across North America, Europe and Asia-Pacific. - Aissel Technologies said interested customers can request a demo at the company's announcement or by emailing sales@aissel.com.

The details: - kAI is built as a conversational intelligence layer for Medical Affairs, Commercial, Clinical, Strategy and MSL teams. - The system lets users ask questions in plain English and get structured outputs without dashboards, filters or technical training. - kAI uses Context Engineering, a retrieval-based architecture that synthesizes data from konectar's continuously updated, curated and validated KOL database before responding. - Aissel Technologies says that approach delivers 95%+ data accuracy, full traceability to source and lower hallucination risk than generic AI tools. - The company says every answer is grounded in verified, structured data. - kAI supports launch readiness intelligence, conference intelligence, KOL lifecycle engagement, geographic influence expansion, brand influence architecture and clinical trial leadership pipeline use cases. - Medical Affairs teams can use kAI to discover and prioritize high-impact KOLs, map congress strategy and track the competitive KOL landscape in real time. - Commercial and sales teams can build launch-ready KOL target lists, refresh outreach priorities and map KOL networks ahead of product launches. - Strategy and leadership teams can use the platform to identify geographic white-space opportunities and compress decision cycles. - kAI is GDPR compliant and supports EU data residency requirements. - Aissel Technologies says KOL data in konectar comes from verified public sources and is managed under applicable privacy and compliance frameworks. - Engagement activity in konectar is fully auditable with complete traceability to source.

Between the lines: - The launch positions Aissel Technologies against generic AI tools by emphasizing grounded answers, source traceability and lower hallucination risk. - The product also reflects a broader shift in life sciences toward AI tools that are tied to structured proprietary data rather than open-ended chat systems. - Prasad Patil, co-founder and CEO of Aissel Technologies, said the goal is to combine generative AI with deeply validated KOL intelligence to help teams make faster, more confident decisions.

What's next: - Aissel Technologies will likely use kAI's launch to deepen adoption inside existing konectar accounts and win new enterprise customers. - The company is also signaling a broader push to make AI-driven decision intelligence a core part of life sciences workflows.

The bottom line: - kAI turns konectar from a KOL intelligence platform into an AI-assisted decision layer for life sciences teams that need speed, accuracy and auditability.